Agios Pharmaceuticals Inc. Stock
A loss of -2.520% shows a downward development for Agios Pharmaceuticals Inc..
Agios Pharmaceuticals Inc. is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a target price of 38 € there is a positive potential of 21.02% for Agios Pharmaceuticals Inc. compared to the current price of 31.4 €.
So far the community has only identified positive things for Agios Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | -2.520% | 1.290% | 12.950% | 30.833% | 52.427% | -32.284% | -26.977% |
| Ironwood Pharmaceuticals | 1.720% | -6.349% | -19.728% | -38.860% | -42.157% | -41.584% | - |
| Novocure Ltd | -2.590% | 34.113% | 97.093% | -69.589% | 56.708% | -85.012% | - |
| Iovance Biotherapeutics Inc. | 0.480% | -5.431% | -10.235% | 40.200% | 22.208% | -37.675% | - |
Comments
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target lowered by analysts at Royal Bank of Canada from $43.00 to $42.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat